Phase II Study of Sunitinib in Thyroid Cancer
Posted: Fri Sep 24, 2010 11:18 pm
There is a result of the Phase II Study of Sunitinib in FDG-PET Positive, Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation
http://clincancerres.aacrjournals.org/c ... 4.abstract
of interest for us the imaging correlation (Repeat FDG-PET was performed on 22 patients, the median percent change in average SUVs was -11.7%, -13.9%, and 8.6% for patients with RECIST response, stable, and progressive disease respectively.), and toxicity (The most common toxicities seen included: fatigue (11%), neutropenia (34%), hand/foot syndrome (17%), diarrhea (17%), and leukopenia (31%). One patient on anticoagulation died of gastrointestinal bleeding.)
Do not take anticoagulats while on these drugs - sunitinib, cediranib etc.
http://clincancerres.aacrjournals.org/c ... 4.abstract
of interest for us the imaging correlation (Repeat FDG-PET was performed on 22 patients, the median percent change in average SUVs was -11.7%, -13.9%, and 8.6% for patients with RECIST response, stable, and progressive disease respectively.), and toxicity (The most common toxicities seen included: fatigue (11%), neutropenia (34%), hand/foot syndrome (17%), diarrhea (17%), and leukopenia (31%). One patient on anticoagulation died of gastrointestinal bleeding.)
Do not take anticoagulats while on these drugs - sunitinib, cediranib etc.